microsoft visio professional 2013 microsoft money 2007 best price adobe indesign cs5
  • download adobe photoshop cs3 for mac os x buy elements 9 download microsoft excel mac 2008
  • download microsoft excel for macintosh purchase windows 7 discount download office 2013 service pack viagra pills australia viagra online in australia cheap viagra newcastle
    buy genuine viagra online in australia buy genuine viagra australia viagra cost per pill australia
    viagra 50mg prix comprar genericos cialis online españa kamagra dove acquistare recensioni
      proscar pharmacie metformin mg amoxil mg
    sildenafil citrato prezzo levitra france cialis super acctive

    New Breath Test to Identify Head and Neck Cancer

    Wed, May 11, 2011

    Oral Cancer News

    Source: British Journal of Cancer

    M Hakim, S Billan, U Tisch, G Peng, I Dvrokind, O Marom, R Abdah-Bortnyak, A Kuten and H Haick



    Head-and-neck cancer (HNC) is the eighth most common malignancy worldwide. It is often diagnosed late due to a lack of screening methods and overall cure is achieved in <50% of patients. Head-and-neck cancer sufferers often develop a second primary tumour that can affect the entire aero-digestive tract, mostly HNC or lung cancer (LC), making lifelong follow-up necessary.


    Alveolar breath was collected from 87 volunteers (HNC and LC patients and healthy controls) in a cross-sectional clinical trial. The discriminative power of a tailor-made Nanoscale Artificial Nose (NA-NOSE) based on an array of five gold nanoparticle sensors was tested, using 62 breath samples. The NA-NOSE signals were analysed to detect statistically significant differences between the sub-populations using (i) principal component analysis with ANOVA and Student’s t-test and (ii) support vector machines and cross-validation. The identification of NA-NOSE patterns was supported by comparative analysis of the chemical composition of the breath through gas chromatography in conjunction with mass spectrometry (GC–MS), using 40 breath samples.


    The NA-NOSE could clearly distinguish between (i) HNC patients and healthy controls, (ii) LC patients and healthy controls, and (iii) HNC and LC patients. The GC–MS analysis showed statistically significant differences in the chemical composition of the breath of the three groups.


    The presented results could lead to the development of a cost-effective, fast, and reliable method for the differential diagnosis of HNC that is based on breath testing with an NA-NOSE, with a future potential as screening tool.


    Print Friendly
    Be Sociable, Share!
    , , , ,

    Leave a Reply

    You must be logged in to post a comment.